BeyondSpring (NASDAQ:BYSI) Shares Down 3.6% – Time to Sell?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price fell 3.6% on Wednesday . The stock traded as low as $1.86 and last traded at $1.90. 16,413 shares were traded during trading, a decline of 54% from the average session volume of 35,649 shares. The stock had previously closed at $1.97.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

BeyondSpring Trading Down 3.6%

The stock has a fifty day moving average of $1.90 and a 200-day moving average of $2.01. The firm has a market capitalization of $76.63 million, a price-to-earnings ratio of -12.67 and a beta of 0.53.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC grew its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the period. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.